



## FOR IMMEDIATE RELEASE

---

### **Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares**

CHICAGO, IL; June 26, 2018 – Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the closing of the Company's initial public offering of 6,555,000 shares of common stock at a public offering price of \$15.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 855,000 shares of common stock. Aggregate gross proceeds to the Company were approximately \$98.3 million, before underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares in the offering were sold by Xeris Pharmaceuticals. Xeris Pharmaceuticals' common stock is listed on The NASDAQ Global Select Market under the ticker symbol "XERS."

Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities acted as joint book running managers for the offering.

A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on June 20, 2018. The offering of these shares was made only by means of a prospectus. Copies of the prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2<sup>nd</sup> Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com); Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37<sup>th</sup> Floor, Boston, MA 02110; by phone at (800) 808-7525, ext. 6132; or by email at [syndicate@leerink.com](mailto:syndicate@leerink.com); RBC Capital Markets LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8<sup>th</sup> Floor, New York, NY 10281; by phone at (877) 822-4089; or by email at [equityprospectus@rbccm.com](mailto:equityprospectus@rbccm.com); or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 320 Park Ave., New York, NY 10022; by phone at (212) 205-7600; or by email at [US-ECM@us.mizuho-sc.com](mailto:US-ECM@us.mizuho-sc.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

#### **About Xeris Pharmaceuticals, Inc.**

Xeris Pharmaceuticals is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, room-temperature stable injectable and infusible drug formulations.

**Xeris Investor Contact**

IR@xerispharma.com

**Xeris Media Contact**

media@xerispharma.com